BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 29417984)

  • 1. [
    Harustiak T; Zemanova M; Fencl P; Hornofova L; Pazdro A; Snajdauf M; Salkova E; Lischke R; Stolz A
    Br J Surg; 2018 Mar; 105(4):419-428. PubMed ID: 29417984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential FDG-PET and induction chemotherapy in locally advanced adenocarcinoma of the Oesophago-gastric junction (AEG): the Heidelberg Imaging program in Cancer of the oesophago-gastric junction during Neoadjuvant treatment: HICON trial.
    Lorenzen S; von Gall C; Stange A; Haag GM; Weitz J; Haberkorn U; Lordick F; Weichert W; Abel U; Debus J; Jäger D; Münter MW
    BMC Cancer; 2011 Jun; 11():266. PubMed ID: 21702914
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessment of diffusion-weighted MRI and 18F-fluoro-deoxyglucose PET/CT in monitoring early response to neoadjuvant chemotherapy in adenocarcinoma of the esophagogastric junction.
    Weber MA; Bender K; von Gall CC; Stange A; Grünberg K; Ott K; Haberkorn U; Kauczor HU; Zechmann C
    J Gastrointestin Liver Dis; 2013 Mar; 22(1):45-52. PubMed ID: 23539390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FDG-PET/CT lymph node staging after neoadjuvant chemotherapy in patients with adenocarcinoma of the esophageal-gastric junction.
    Fencl P; Belohlavek O; Harustiak T; Zemanova M
    Abdom Radiol (NY); 2016 Nov; 41(11):2089-2094. PubMed ID: 27405645
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metabolic tumour and nodal response to neoadjuvant chemotherapy on FDG PET-CT as a predictor of pathological response and survival in patients with oesophageal adenocarcinoma.
    Moore JL; Subesinghe M; Santaolalla A; Green M; Deere H; Van Hemelrijck M; Lagergren J; Chicklore S; Maisey N; Gossage JA; Kelly M; Baker CR; Davies AR;
    Eur Radiol; 2023 May; 33(5):3647-3659. PubMed ID: 36920518
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor response to neoadjuvant chemotherapy in patients with esophageal cancer assessed with CT and FDG-PET/CT - RECIST 1.1 vs. PERCIST 1.0.
    Odawara S; Kitajima K; Katsuura T; Kurahashi Y; Shinohara H; Yamakado K
    Eur J Radiol; 2018 Apr; 101():65-71. PubMed ID: 29571803
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Locally advanced esophageal adenocarcinoma: response to neoadjuvant chemotherapy and survival predicted by ([18F])FDG-PET/CT.
    Kauppi JT; Oksala N; Salo JA; Helin H; Karhumäki L; Kemppainen J; Sihvo EI; Räsänen JV
    Acta Oncol; 2012 May; 51(5):636-44. PubMed ID: 22208782
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PET to assess early metabolic response and to guide treatment of adenocarcinoma of the oesophagogastric junction: the MUNICON phase II trial.
    Lordick F; Ott K; Krause BJ; Weber WA; Becker K; Stein HJ; Lorenzen S; Schuster T; Wieder H; Herrmann K; Bredenkamp R; Höfler H; Fink U; Peschel C; Schwaiger M; Siewert JR
    Lancet Oncol; 2007 Sep; 8(9):797-805. PubMed ID: 17693134
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimizing neoadjuvant chemotherapy through the use of early response evaluation by positron emission tomography.
    Lordick F
    Recent Results Cancer Res; 2012; 196():201-11. PubMed ID: 23129376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perioperative EOX treatment in operable locally advanced gastroesophageal adenocarcinoma: Prediction of tumor response by FDG -PET and histopathology.
    Vihervaara H; Ålgars A; Kemppainen J; Sundström J; Ristamäki R; Salminen P
    Surg Oncol; 2019 Mar; 28():42-49. PubMed ID: 30851910
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prediction of tumor response by FDG-PET: comparison of the accuracy of single and sequential studies in patients with adenocarcinomas of the esophagogastric junction.
    Wieder HA; Ott K; Lordick F; Becker K; Stahl A; Herrmann K; Fink U; Siewert JR; Schwaiger M; Weber WA
    Eur J Nucl Med Mol Imaging; 2007 Dec; 34(12):1925-32. PubMed ID: 17680242
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Lehmann K; Eshmuminov D; Bauerfeind P; Gubler C; Veit-Haibach P; Weber A; Abdul-Rahman H; Fischer M; Reiner C; Schneider PM
    Eur J Surg Oncol; 2017 Jan; 43(1):196-202. PubMed ID: 27692533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic role of early 18-FDG PET/CT during neoadjuvant chemotherapy for resectable adenocarcinoma of the esophagus and esophagogastric junction.
    Harustiak T; Zemanova M; Fencl P; Pazdro A; Snajdauf M; Faltova H; Lischke R; Stolz AJ
    Neoplasma; 2021 Mar; 68(2):423-433. PubMed ID: 33440988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The value of 18F-FDG-PET testing in the management of esophageal and gastroesophageal junction adenocarcinoma - review.
    Zemanová M; Obermannová R; Haruštiak T
    Klin Onkol; 2021; 34(2):113-119. PubMed ID: 33906359
    [TBL] [Abstract][Full Text] [Related]  

  • 15.
    Schneider PM; Eshmuminov D; Rordorf T; Vetter D; Veit-Haibach P; Weber A; Bauerfeind P; Samaras P; Lehmann K
    BMC Cancer; 2018 May; 18(1):548. PubMed ID: 29743108
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Accuracy and reproducibility of 3D-CT measurements for early response assessment of chemoradiotherapy in patients with oesophageal cancer.
    van Heijl M; Phoa SS; van Berge Henegouwen MI; Omloo JM; Mearadji BM; Sloof GW; Bossuyt PM; Hulshof MC; Richel DJ; Bergman JJ; Ten Kate FJ; Stoker J; van Lanschot JJ
    Eur J Surg Oncol; 2011 Dec; 37(12):1064-71. PubMed ID: 21944048
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of positron emission tomography-computed tomography in predicting survival after neoadjuvant chemotherapy and surgery for oesophageal adenocarcinoma.
    Gillies RS; Middleton MR; Han C; Marshall RE; Maynard ND; Bradley KM; Gleeson FV
    Br J Surg; 2012 Feb; 99(2):239-45. PubMed ID: 22329010
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluorodeoxyglucose positron emission tomography for evaluating early response during neoadjuvant chemoradiotherapy in patients with potentially curable esophageal cancer.
    van Heijl M; Omloo JM; van Berge Henegouwen MI; Hoekstra OS; Boellaard R; Bossuyt PM; Busch OR; Tilanus HW; Hulshof MC; van der Gaast A; Nieuwenhuijzen GA; Bonenkamp HJ; Plukker JT; Cuesta MA; Ten Kate FJ; Pruim J; van Dekken H; Bergman JJ; Sloof GW; van Lanschot JJ
    Ann Surg; 2011 Jan; 253(1):56-63. PubMed ID: 21233607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant radio-chemotherapy of adenocarcinoma of the oesophagogastric junction.
    Samel S; Hofheinz R; Hundt A; Sturm J; Knoll MR; Wenz F; Queisser W; Post S
    Onkologie; 2001 Jun; 24(3):278-82. PubMed ID: 11455222
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early repeated 18F-FDG PET scans during neoadjuvant chemoradiation fail to predict histopathologic response or survival benefit in adenocarcinoma of the esophagus.
    Malik V; Lucey JA; Duffy GJ; Wilson L; McNamara L; Keogan M; Gillham C; Reynolds JV
    J Nucl Med; 2010 Dec; 51(12):1863-9. PubMed ID: 21078796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.